India, May 2 -- India primarily exports generic medicines to a large number of countries, including developed nations, helping reduce healthcare costs globally, and the country's intellectual property rights regime is fully compliant with global trade rules, think tank GTRI said on Friday. India supplies nearly 20 per cent of global generic medicines, making its IP stance globally significant, it said. India has again been placed on the Priority Watch List in the 2026 Special 301 Report released on April 30 by the Office of the United States Trade Representative (USTR), reflecting continued US pressure over pharmaceutical-related intellectual property protection and enforcement in India, it said. The Special 301 process is not legally bin...